与其他β-阻断剂/前列腺素FP受体激动剂固定组合眼科溶液相比,卡尔特洛洛化/拉坦诺普罗斯特固定组合眼科溶液的持久性
Kenji Kashiwagi1, Kentaro Ouchi2, Yoshiyuki Shibasaki2
1Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, 1110, Shimokato, Chuo, Yamanashi, 409-3898, Japan. kenjik@yamanashi.ac.jp.
Japanese journal of ophthalmology
|August 18, 2023
概括
卡尔特醇化物/拉塔诺普罗斯特 (CAR/LAT) 眼科溶液显示,与其他β-阻断剂/前列腺素FP受体激动剂 (BB/FP) 组合相比,在青光眼患者中,治疗持续时间显著更长. 这一发现突出了患者坚持固定组合格洛科马治疗的潜在差异.
科学领域:
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 青光眼的管理需要长期坚持治疗.
- 固定组合眼滴的目的是改善患者的服药性.
- 贝塔抑制剂/前列腺素FP受体激动剂 (BB/FP) 组合通常用于青光眼.
研究的目的:
- 为了比较卡尔特洛洛化/拉坦诺普罗斯特固定组合眼科溶液 (CAR/LAT) 与其他BB/FP固定组合眼科溶液的治疗持久性.
- 为了评估现实世界患者对不同固定的组合绿眼治疗的坚持.
主要方法:
- 使用JMDC索赔数据库进行的回顾性观察队列研究.
- 包括在2017年2月至2020年3月期间被诊断患有青光眼的20岁以上患者.
- 在CAR/LAT组与其他BB/FP组之间比较治疗持久性.
主要成果:
- 分析了16,612名患者 (7423名在CAR/LAT,9189名在其他BB/FP).
- 与其他BB/FP相比,CAR/LAT组的治疗持续时间明显更长 (HR 0.747,p < 0.0001).
- 对CAR/LAT的中位治疗持续时间为135天,对其他BB/FP的治疗持续时间为97天.
结论:
- 治疗持久性在固定的组合BB/FP眼科解决方案之间有所不同.
- 与其他BB/FP组合相比,CAR/LAT表现出优越的治疗持久性.
- 调查结果表明,CAR/LAT可能会在绿眼管理中提供更好的长期坚持.
相关概念视频
Adrenergic Antagonists: ɑ and β-Receptor Blockers
511
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
511
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
663
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
663
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
890
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
890
Open Angle Glaucoma: Treatment
477
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
477
Antiasthma Drugs: β2-Adrenoceptor Agonists
299
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
299


